Catalent Pharma Solutions has acquired an exclusive license to market Redwood Bioscience’s SMARTag precision protein-chemical engineering technology for the development of advanced antibody-drug conjugates (ADCs). Redwood’s site-specific protein modification and linker technologies enable the generation of homogenous bioconjugates engineered to enhance potency, safety and stability.
Catalent will have the exclusive right to sub-license the SMARTag technology to customers and will work with Redwood to co-market the technology and support sub-license programs. As part of the collaboration, Catalent will also take a minority equity stake in Redwood, with the potential to increase over time. Financial terms were not disclosed.
“Our goal is to enable our biologics customers to create more and better treatments through advanced technologies and development solutions,” said Barry Littlejohns, president of Catalent Medication Delivery Solutions “We believe that Redwood is an industry leader in site-specific conjugation. Their innovative technologies will provide significant value to our customers looking to develop next-generation ADC therapies.”
David Rabuka Ph.D., Redwood’s co-founder and chief scientific officer, said, “We are very excited to be closely allied with Catalent. The technical synergy between Redwood and Catalent is a unique opportunity to provide unparalleled access to the next generation of bioconjugates."